Use of Anti-Interleukin-6 Receptor Monoclonal Antibody in Drug-Induced Acute Respiratory Distress Syndrome
| Autor: | Noa Biran, Sean Sadikot, Alessandra Petrillo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Drug
ARDS Innate immune system medicine.drug_class business.industry RC86-88.9 media_common.quotation_subject Case Report Medical emergencies. Critical care. Intensive care. First aid 030204 cardiovascular system & hematology Lung injury Critical Care and Intensive Care Medicine Monoclonal antibody medicine.disease Proinflammatory cytokine 03 medical and health sciences 0302 clinical medicine Interleukin-6 receptor Immunology medicine 030212 general & internal medicine business Multiple myeloma media_common |
| Zdroj: | Case Reports in Critical Care, Vol 2020 (2020) Case Reports in Critical Care |
| ISSN: | 2090-6439 2090-6420 |
| Popis: | Acute respiratory distress syndrome (ARDS) is a disorder that involves the activation of alveolar macrophages triggering the innate immune system. The parenchymal lung injury seen in ARDS is a result of many proinflammatory elevations including interleukin-6. There remains no effective standard of care of ARDS, and current treatments at this time currently do not target the immunological mechanisms or pathways involved. Treatments involving this pathway should be further investigated as targeted treatment. We discuss a case of a patient with multiple myeloma who was hospitalized with drug-induced ARDS who had a rapid response to an anti-interleukin-6 monoclonal antibody. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text